Moderna (NASDAQ:MRNA) Given New $179.00 Price Target at Oppenheimer

Moderna (NASDAQ:MRNA) had its target price upped by Oppenheimer from $163.00 to $179.00 in a report issued on Wednesday morning, Benzinga reports. Oppenheimer currently has an outperform rating on the stock.

MRNA has been the topic of a number of other reports. UBS Group raised their target price on Moderna from $143.00 to $151.00 and gave the stock a buy rating in a report on Tuesday, May 7th. Jefferies Financial Group reaffirmed a buy rating and issued a $125.00 price objective on shares of Moderna in a research note on Tuesday, April 9th. Canaccord Genuity Group increased their target price on shares of Moderna from $91.00 to $106.00 and gave the stock a hold rating in a report on Friday, May 3rd. Needham & Company LLC reaffirmed a hold rating on shares of Moderna in a report on Monday, June 3rd. Finally, William Blair reiterated a market perform rating on shares of Moderna in a research report on Monday, April 1st. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of Hold and a consensus target price of $129.02.

Moderna Stock Down 3.6 %

MRNA stock opened at $140.03 on Wednesday. The company has a market cap of $53.67 billion, a price-to-earnings ratio of -8.94 and a beta of 1.54. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.91 and a current ratio of 4.03. The business’s 50-day moving average is $128.95 and its two-hundred day moving average is $108.37. Moderna has a fifty-two week low of $62.55 and a fifty-two week high of $170.47.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, topping the consensus estimate of ($3.59) by $0.52. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The firm had revenue of $167.00 million for the quarter, compared to analysts’ expectations of $93.26 million. During the same quarter in the prior year, the business earned $0.19 EPS. The business’s quarterly revenue was down 91.0% on a year-over-year basis. As a group, analysts forecast that Moderna will post -7.46 earnings per share for the current year.

Insider Activity at Moderna

In other news, President Stephen Hoge sold 15,000 shares of the business’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $105.02, for a total value of $1,575,300.00. Following the sale, the president now directly owns 1,486,241 shares in the company, valued at approximately $156,085,029.82. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, President Stephen Hoge sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $105.02, for a total value of $1,575,300.00. Following the completion of the sale, the president now directly owns 1,486,241 shares of the company’s stock, valued at approximately $156,085,029.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Noubar Afeyan sold 202,832 shares of the business’s stock in a transaction that occurred on Tuesday, June 11th. The shares were sold at an average price of $148.34, for a total value of $30,088,098.88. Following the transaction, the director now directly owns 1,528,557 shares in the company, valued at approximately $226,746,145.38. The disclosure for this sale can be found here. Insiders have sold a total of 411,255 shares of company stock valued at $55,309,981 over the last 90 days. 15.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Moderna

A number of large investors have recently made changes to their positions in the company. Ogorek Anthony Joseph NY ADV purchased a new stake in Moderna in the 4th quarter worth about $27,000. Arlington Trust Co LLC raised its holdings in shares of Moderna by 4,833.3% in the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock worth $29,000 after buying an additional 290 shares during the period. Cedar Wealth Management LLC lifted its stake in shares of Moderna by 45.0% during the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after acquiring an additional 90 shares during the last quarter. Westside Investment Management Inc. purchased a new position in Moderna during the 1st quarter valued at $32,000. Finally, Rise Advisors LLC grew its position in Moderna by 953.3% in the 1st quarter. Rise Advisors LLC now owns 316 shares of the company’s stock valued at $34,000 after acquiring an additional 286 shares during the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.